Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Pometta

Showing results (41-50 of 95) with videos related to

Pageof 10
Sort By:
Schweizerische Medizinische Wochenschrift|December 16, 1989
[Remnant disease associated with apoprotein E1; clinical importance of apoprotein E (apo E) phenotypes]I Borghini, R W James, D Pometta
Schweizerische Medizinische Wochenschrift|December 17, 1983
[HDL-cholesterol and family incidence of coronary disease in the Genevan population]A Suenram, D Pometta, N von der Weid
Pharmacological Research Communications|February 1, 1984
Apparent lack of influence of the genetic drug oxidation status on plasma cholesterol concentration in manP Dayer, A Suenram, D Pometta, et al.
Atherosclerosis|December 1, 1979
HDL lipids in close relatives of coronary heart disease patients. Environmental and genetic influencesD Pometta, H Micheli, A Suenram, et al.
Schweizerische Medizinische Wochenschrift|January 24, 1981
[HDL and lipoproteins in the families of coronary patients]D Pometta, H Micheli, A Suenram, et al.
Lancet (London, England)|June 9, 1973
Clofibrate, nephrotic syndrome, and histological changes in muscleM Denizot, J Fabre, D Pometta, et al.
Schweizerische Medizinische Wochenschrift|December 12, 1987
[Apoprotein E (apo E) phenotype and serum lipids in diabetics]R W James, C Voliotis, B Grab, et al.
Biochimica Et Biophysica Acta|March 16, 1995
Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluidI Borghini, F Barja, D Pometta, et al.
Schweizerische Medizinische Wochenschrift|August 21, 1993
[Comparison of 2 cholesterol synthesis inhibitors (simvastatin and pravastatin)]A Golay, T Lehmann, R James, et al.
Metabolism: Clinical and Experimental|August 1, 1988
The influence of metabolic control on very low density lipoprotein composition in hypertriglyceridemic type II diabetics. A study using heparin-sepharose chromatographyJ Leowsky, R W James, J Taton, et al.
Pageof 10

Showing results (41-50 of 95) with videos related to

Sort By:
Pageof 10
Schweizerische Medizinische Wochenschrift|December 16, 1989
[Remnant disease associated with apoprotein E1; clinical importance of apoprotein E (apo E) phenotypes]I Borghini, R W James, D Pometta
Schweizerische Medizinische Wochenschrift|December 17, 1983
[HDL-cholesterol and family incidence of coronary disease in the Genevan population]A Suenram, D Pometta, N von der Weid
Pharmacological Research Communications|February 1, 1984
Apparent lack of influence of the genetic drug oxidation status on plasma cholesterol concentration in manP Dayer, A Suenram, D Pometta, et al.
Atherosclerosis|December 1, 1979
HDL lipids in close relatives of coronary heart disease patients. Environmental and genetic influencesD Pometta, H Micheli, A Suenram, et al.
Schweizerische Medizinische Wochenschrift|January 24, 1981
[HDL and lipoproteins in the families of coronary patients]D Pometta, H Micheli, A Suenram, et al.
Lancet (London, England)|June 9, 1973
Clofibrate, nephrotic syndrome, and histological changes in muscleM Denizot, J Fabre, D Pometta, et al.
Schweizerische Medizinische Wochenschrift|December 12, 1987
[Apoprotein E (apo E) phenotype and serum lipids in diabetics]R W James, C Voliotis, B Grab, et al.
Biochimica Et Biophysica Acta|March 16, 1995
Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluidI Borghini, F Barja, D Pometta, et al.
Schweizerische Medizinische Wochenschrift|August 21, 1993
[Comparison of 2 cholesterol synthesis inhibitors (simvastatin and pravastatin)]A Golay, T Lehmann, R James, et al.
Metabolism: Clinical and Experimental|August 1, 1988
The influence of metabolic control on very low density lipoprotein composition in hypertriglyceridemic type II diabetics. A study using heparin-sepharose chromatographyJ Leowsky, R W James, J Taton, et al.
Pageof 10